Get started
Author

Pacôme Prompsy

Observed names: P. Prompsy, Pacome Prompsy, Pacôme B. Prompsy, Prompsy, Pacome, Prompsy, Pacôme
Observed institutions: Johannes Kepler University of Linz, Centre National de la Recherche Scientifique, Université de Montpellier, Université Paris Sciences et Lettres, Centre Hospitalier Universitaire Vaudois, Hudson Institute of Medical Research, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Dynamique de l'information génétique : bases fondamentales et cancer, Laboratoire de Biotechnologie de l'Environnement, Hôpital Orthopédique de la Suisse Romande, Kepler Universitätsklinikum, Monash University, Institut Curie, University of Lausanne
ORCID: 0000-0003-4375-7583
Observed ORCID: 0000-0003-4375-7583
OpenAlex ID: A5087832103
H3K27me3 conditions chemotolerance in triple-negative breast cancer
2022 · Justine Marsolier, Pacôme Prompsy, et al. · Nature Genetics · 194
PDF
Th17-associated cytokines IL-17 and IL-23 in inflamed skin of Darier disease patients as potential therapeutic targets
2023 · Monika Ettinger, Teresa Burner, et al. · Nature Communications · 42
PDF
Interactive analysis of single-cell epigenomic landscapes with ChromSCape
2020 · Pacôme Prompsy, Pia Kirchmeier, et al. · Nature Communications · 31
PDF
Enhancement of corn stover conversion to carboxylates by extrusion and biotic triggers in solid-state fermentation
2018 · Antonella Marone, Eric Trably, et al. · Applied Microbiology and Biotechnology · 20
MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides
2024 · Yun-Tsan Chang, Pacôme Prompsy, et al. · Nature Communications · 18
PDF
A benchmark of computational pipelines for single-cell histone modification data
2023 · Félix Raimundo, Pacôme Prompsy, et al. · Genome biology · 14
PDF
Epigenomic disorder and partial EMT impair luminal progenitor integrity in Brca1-associated breast tumorigenesis
2025 · Camille Landragin, Melissa Saichi, et al. · Molecular Cancer · 13
PDF
Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2025 · Léa Baudre, Grégoire Jouault, et al. · Cancer Research · 12
PDF
Luminal progenitors undergo partial epithelial-to-mesenchymal transition at the onset of basal-like breast tumorigenesis
2022 · Camille Landragin, Melissa Saichi, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
Making use of transcription factor enrichment to identify functional microRNA-regulons
2021 · Pacôme B. Prompsy, John Toubia, et al. · Computational and Structural Biotechnology Journal · 5
PDF
Evaluating T Cell Clonality in Skin using a Quantitative TRBC1 – Clonality Score
2025 · Christoph Iselin, Pacôme Prompsy, et al. · Journal of Investigative Dermatology · 2
PDF
Multiharmonic imaging-based automated recognition of cutaneous T-cell lymphoma
2025 · Shayantani Ghosh, Olesya Pavlova, et al. · British Journal of Dermatology · 2
PDF
IDclust: Iterative clustering for unsupervised identification of cell types with single cell transcriptomics and epigenomics
2024 · Pacôme Prompsy, Mélissa Saichi, et al. · NAR Genomics and Bioinformatics · 1
PDF
LY01 Quantitative and functional alterations of B cells in cutaneous T-cell lymphomas
2026 · Gabriele Roccuzzo, Yun-Tsan Chang, et al. · British Journal of Dermatology
Figure S1 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Table S4 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Figure S3 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Figure S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Table S3 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Data from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Figure S5 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Table S1 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Table S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Table S5 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Figure S4 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
2026 · Léa Baudre, Grégoire Jouault, et al.
Works count: 64
Citation count: 361
H-index: 8
I10-index: 8
Year
Topic
Type